ライフサイエンスコーパス: gabapentin

1 stsynaptic blockade of calcium channels (for gabapentin).

2 le and ropinirole) and alpha2 delta ligands (gabapentin).

3 that was also reversed by pre-incubation in gabapentin.

4 e pain during neuropathy that is reversed by gabapentin.

5 or for the anti-epileptic and analgesic drug gabapentin.

6 h amitriptyline, carbamazepine, diazepam and gabapentin.

7 e taking the placebo and in some patients on gabapentin.

8 domain of thrombospondin-2 was prevented by gabapentin.

9 d research, were extensively used to promote gabapentin.

10 ad complete resolution of nausea when taking gabapentin.

11 , after she was placed on the anticonvulsant gabapentin.

12 rmine the specificity of hBCATc for the drug gabapentin.

13 4 patients enrolled in an open-lbel trial of gabapentin.

14 dorsal horn neurons that could be blocked by gabapentin.

15 with highest correlations for acesulfame and gabapentin.

16 from slices that had been pre-incubation in gabapentin.

17 CaV2.2 and alpha2delta-1 is not disrupted by gabapentin.

18 pine and have been successfully treated with gabapentin.

19 ts noted improvement in symptoms when taking gabapentin.

20 effects more potently and efficaciously than gabapentin.

21 e half were pre-incubated in aCSF containing gabapentin.

22 of newer antidepressants and three trials of gabapentin.

23 ome reporting for trials of off-label use of gabapentin.

24 (hazard ratio [HR] 0.78 [95% CI 0.63-0.97]), gabapentin (0.65 [0.52-0.80]), and topiramate (0.64 [0.5

25 carbamazepine was significantly better than gabapentin (0.75 [0.63-0.90]), and estimates suggest a n

26 , double-blind study was designed to compare gabapentin (1,200-2,400 mg/day) (n=75 patients) with pla

27 Gabapentin (1,200-2,400 mg/day) is safe and efficacious

28 ed a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) fo

29 the first time that the alpha2delta ligands gabapentin [1-(aminomethyl)cyclohexaneacetic acid] and p

30 Subjects received either gabapentin (1200 mg/day) or matched placebo.

31 95; 95% CI, -1.44 to -0.47), and 2 trials of gabapentin (-2.05; 95% CI, -2.80 to -1.30).

32 y whereas intrathecal morphine (1microg) and gabapentin (200microg) partially reversed thermal and me

33 ed to be higher in patients taking high-dose gabapentin (3,300-3,600 mg/day) than in those taking sta

34 is, we did an open-label study in which oral gabapentin 300 mg thrice daily was given for every other

35 900 mg) and 347 at 8 weeks (113 placebo, 114 gabapentin 300 mg, and 120 gabapentin 900 mg).

36 71 participants at 4 weeks (119 placebo, 123 gabapentin 300 mg, and 129 gabapentin 900 mg) and 347 at

37 shes per day were randomly assigned placebo, gabapentin 300 mg/day, or gabapentin 900 mg/day by mouth

38 43) and 31% (16 to 46) in the group assigned gabapentin 300 mg; and 49% (42 to 56) and 46% (34 to 58)

39 Gabapentin (50mg/kg, i.p.) significantly reduced vlPAG n

40 (119 placebo, 123 gabapentin 300 mg, and 129 gabapentin 900 mg) and 347 at 8 weeks (113 placebo, 114

41 (113 placebo, 114 gabapentin 300 mg, and 120 gabapentin 900 mg).

42 56) and 46% (34 to 58) in the group assigned gabapentin 900 mg.

43 assigned placebo, gabapentin 300 mg/day, or gabapentin 900 mg/day by mouth in three divided doses fo

44 We conducted a gabapentin (900 mg) challenge in healthy human subjects

45 m of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patient

46 e oligonucleotides to knock down Cavbeta and gabapentin, a drug that binds to and inhibits alpha2delt

47 ng pain; thus, there is a rationale to study gabapentin, a drug that increases the threshold to exper

48 Gabapentin, a drug useful in several neurological and ps

49 micked the effect of conditioned medium, and gabapentin, a high-affinity antagonist of TSP binding to

50 Blocking Cavalpha2delta1 with gabapentin, a ligand for the Cavalpha2delta1 proteins, o

51 s in nucleus accumbens, we demonstrated that gabapentin, a specific alpha2delta-1 antagonist, prefere

52 enaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal a

53 sis, and medications such as venlafaxine and gabapentin.Additional information is available at: www.a

54 a provide complementary new information that gabapentin administered systemically and spinally can ef

55 verage 5.6%) and between day (average 4.8%), gabapentin administration was associated with an average

56 may account for the differential effects of gabapentin after chronic ethanol.

57 ined treatment v 49%; 95% CI, 26% to 58% for gabapentin alone) and scores (56%; 95% CI, 26% to 71% fo

58 ined treatment v 60%; 95% CI, 33% to 73% for gabapentin alone).

59 ctively alleviate hot flashes, compared with gabapentin alone, in patients with inadequate hot flash

60 weaned off the antidepressant and receiving gabapentin alone.

61 ntrathecal administration of 10-30 microg of gabapentin also produced a significant effect on the mec

62 The effect of gabapentin, an anticonvulsant drug that is also effectiv

63 Pretreatment with gabapentin, an inhibitor of the alpha2delta1 subunit, bl

64 Eighty-four patients received gabapentin and 70 (83%) completed the study; 81 received

65 d for treatment of neuropathic pain, such as gabapentin and amitriptyline.

66 enytoin proved ineffective, while valproate, gabapentin and carbamazepine varied in their potencies,

67 Gabapentin and duloxetine reversed mechanical hyperalges

68 Side effects included unsteadiness with gabapentin and lethargy with memantine.

69 ast potential interaction is associated with gabapentin and levetiracetam.

70 l antiepileptic agents, including valproate, gabapentin and phenytoin, reduced the ability of astrocy

71 target of the potent neuropathic analgesics gabapentin and pregabalin (alpha2delta-1 and alpha2delta

72 The therapeutic drugs gabapentin and pregabalin (PGB), which are both alpha(2)

73 ostherpetic neuralgia compared with placebo, gabapentin and pregabalin are associated with a modest i

74 Gabapentin and pregabalin are structurally related compo

75 The interaction of gabapentin and pregabalin with conventional antiepilepti

76 effectiveness of the alpha-2-delta ligands (gabapentin and pregabalin) and the norepinephrine/seroto

77 ponsive to a variety of therapies, including gabapentin and topiramate.

78 ly comparable to what has been reported with gabapentin and with some newer antidepressants.

79 tremor patients (primidone, propranolol, and gabapentin) and several candidates hypothesized to reduc

80 One hundred thirteen patients received gabapentin, and 89 (78.8%) completed the study; 116 rece

81 lic antidepressants (such as nortriptyline), gabapentin, and a compounded topical gel containing bacl

82 LRP1 regulates alpha2delta binding to gabapentin, and influences calcium channel trafficking a

83 athic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors.

84 clonidine, soy phyto-oestrogens, vitamin E, gabapentin, and several of the newer antidepressants, wi

85 Gabapentin antagonizes the interaction of thrombospondin

86 Gabapentin antagonizes thrombospondin binding to alpha2d

87 Gabapentin appears to increase human brain GABA levels.

88 sion in the literature regarding efficacy of gabapentin as a candidate addiction therapy.

89 The use of gabapentin as an effective analgesic agent for neuropath

90 pha2delta amino acid, R217A, eliminates both gabapentin binding and analgesic efficacy.

91 ison suggests that alpha(2)delta-4 lacks the gabapentin binding motifs characterized for alpha(2)delt

92 2+) -dependent reduction in affinity of (3)H-gabapentin binding to alpha2delta-1.

93 However, the effect on (3)H-gabapentin binding was not reproduced by the synaptogeni

94 ha2delta-1 might reciprocally influence (3)H-gabapentin binding.

95 pha(2)delta-2; this was confirmed by a [(3)H]gabapentin-binding assay.

96 In vitro studies indicate that gabapentin binds to the alpha(2)delta-1 (hereafter refer

97 ), visual acuity improved significantly with gabapentin, but not with baclofen.

98 drugs reduced median eye speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved

99 so determined electrophysiologically whether gabapentin causes displacement of beta subunits from Ca(

100 GABA was elevated in patients taking gabapentin compared with 14 complex partial epilepsy pat

101 Gabapentin compared with placebo also significantly impr

102 In conclusion, gabapentin did not provide a significant therapeutic adv

103 ubunit but not in the presence of beta4b; 3) gabapentin does not affect Ca(v)2.1 voltage-dependent ga

104 Gabapentin does not seem to have direct Ca2+ channel blo

105 nued on their current antidepressant without gabapentin) during which time they completed validated d

106 Gabapentin effects on glutamate are not known.

107 In this report, we examined gabapentin effects on trafficking and voltage-dependent

108 Gabapentin effects were blocked in the presence of a spe

109 in; 7.2 (5.9-9.21) for gabapentin, including gabapentin extended release and enacarbil; and 10.6 (7.4

110 panies to develop and publish articles about gabapentin for the medical literature, and planning to s

111 dies has evaluated newer antidepressants and gabapentin for treating hot flashes.

112 inary support for the safety and efficacy of gabapentin for treatment of cannabis dependence that mer

113 that opioids, tramadol, benzodiazepines, and gabapentin (for radiculopathy) are effective for pain re

114 y of a calcium channel/GABA modulating drug, gabapentin, for the treatment of cannabis dependence.

115 e examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidi

116 Gabapentin (GBP) and S(+)-3-isobutyl-gamma-aminobutyric

117 The antiepileptic and antiallodynic drug gabapentin (GBP) binds to the alpha2delta-1 and alpha2de

118 he effects of electroacupuncture (EA) versus gabapentin (GP) for hot flashes among survivors of breas

119 Confusion was also more frequent in the gabapentin group (7 [8%] vs 1 [1.2%]; P = .06).

120 During the first 6 weeks, the naltrexone-gabapentin group had a longer interval to heavy drinking

121 res of pain were significantly better in the gabapentin group than in the placebo group.

122 omparable in the 2 groups (15 [13.3%] in the gabapentin group vs 11 [9.5%] in the placebo group).

123 pentin group were dizziness (20 [24%] in the gabapentin group vs 4 [4.9%] in the control group; P<.00

124 oup; P<.001) and somnolence (19 [23%] in the gabapentin group vs 5 [6%] in the control group; P = .00

125 rienced significantly more frequently in the gabapentin group were dizziness (20 [24%] in the gabapen

126 and infection were all more frequent in the gabapentin group, but withdrawals were comparable in the

127 rexone-alone group but not in the naltrexone-gabapentin group, while a history of alcohol withdrawal

128 iated with better response in the naltrexone-gabapentin group.

129 intent-to-treat analysis, subjects receiving gabapentin had a statistically significant reduction in

130 Moreover, gabapentin had no effect on reinstatement of sucrose see

131 These findings indicate that gabapentin has a measurable antinociceptive effect and a

132 Gabapentin has come into clinical use as adjunctive ther

133 he alpha-2-delta receptor modulators such as gabapentin have shown early promising results in multimo

134 The risk of suicidal acts was increased for gabapentin (hazard ratio [HR], 1.42; 95% confidence inte

135 Gabapentin impairs the T-cell receptor-driven calcium re

136 racetamol and opiates in 97% of patients and gabapentin in 45% of patients.

137 e beneficial effect of Cavbeta antisense and gabapentin in allergic airway inflammation.

138 nstitutional trial to assess the efficacy of gabapentin in controlling hot flashes in women with brea

139 To assess the efficacy and safety of gabapentin in patients with fibromyalgia.

140 Intraperitoneal injection of 30-60 mg/kg of gabapentin in resiniferotoxin-treated rats significantly

141 CaV2.2 cell-surface expression is reduced by gabapentin in the presence of wild-type alpha2delta-1 (b

142 ould be employed when considering the use of gabapentin in transplant recipients, especially when com

143 oes not alter cP450 enzymes (lamotrigine and gabapentin) in monotherapy for 6 months or more were fol

144 (6.5-9.4) for pregabalin; 7.2 (5.9-9.21) for gabapentin, including gabapentin extended release and en

145 Gabapentin increased the amplitudes of evoked GABA recep

146 (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in respo

147 Gabapentin infused directly into the CeA also blocked de

148 use selective inhibition of alpha2delta-1 by gabapentin infusion into wild-type VMH significantly inc

149 v)2.1 Ca2+ channels in X. laevis oocytes; 2) gabapentin inhibition occurs in the presence of the Ca2+

150 endent on beta-subunit concentration; and 5) gabapentin inhibition of Ca(v)2.1 trafficking can be rev

151 Our principal findings are as follows: 1) gabapentin inhibits trafficking of recombinant Ca(v)2.1

152 e.g., capsaicin), antiepileptic drugs (e.g., gabapentin), injection of other agents (e.g., botulinum

153 esence of wild-type alpha2delta-1 (but not a gabapentin-insensitive alpha2delta-1 mutant), the intera

154 The alpha2delta ligand gabapentin interacts with alpha2delta-1, and inhibits ca

155 minophen are preferred analgesic agents, and gabapentin is a contextual third choice, in neurocritica

156 y target pathological channels; for example, gabapentin is a ligand of alpha2delta voltage-activated

157 Gabapentin is a nonhormonal agent that also can reduce h

158 Gabapentin is a structural analog of GABA that has antic

159 concentrations predict clinical efficacy of gabapentin is an area worthy of exploration.

160 This mechanism may help to explain why gabapentin is both effective and selective in the treatm

161 The anticonvulsant gabapentin is effective in reducing the subjective pain

162 Gabapentin is effective in the control of hot flashes at

163 Gabapentin is effective in the treatment of pain and sle

164 activation, thus supporting the concept that gabapentin is more effective in modulating nociceptive t

165 Gabapentin is well established as an effective treatment

166 Despite the therapeutic efficacy of gabapentin, its molecular and cellular mechanisms of act

167 nd marketed in the United States: felbamate, gabapentin, lamotrigine, and topiramate.

168 iepileptic drugs selected for discussion are gabapentin, lamotrigine, felbamate, vigabatrin, and topi

169 In contrast, the new AEDs gabapentin, lamotrigine, levetiracetam, tiagabine, topir

170 xploratory analysis suggests that the use of gabapentin, lamotrigine, oxcarbazepine, and tiagabine, c

171 randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

172 randomly assigned to receive carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate.

173 Gabapentin, marketed for the treatment of seizures and n

174 Our findings suggest that gabapentin may be an effective treatment for many patien

175 We suggest that gabapentin may cause acute renal dysfunction by a mechan

176 xcitatory synapse formation and suggest that gabapentin may function therapeutically by blocking new

177 Gabapentin may reduce these symptoms and help prevent ea

178 neration antipsychotics, iliac fascia block, gabapentin, melatonin, lower levels of intraoperative pr

179 In vivo, gabapentin microinjected in the nucleus accumbens core a

180 This preliminary evidence shows that gabapentin might have a role in treatment of chemotherap

181 Gabapentin monotherapy appears to be efficacious for the

182 uli was sensitive to systemic treatment with gabapentin, morphine and the cannabinoid WIN 55,212-2, b

183 addition, IB-MECA was equally efficacious as gabapentin (Neurontin) or amitriptyline, but respectivel

184 rough litigation concerning the promotion of gabapentin (Neurontin, Pfizer, Inc., New York, New York)

185 tructurally and pharmacologically related to gabapentin (Neurontin; Pfizer Inc., New York, NY).

186 in turn, dependence reverses the effects of gabapentin on CeA neurons, and suggest that gabapentin r

187 Here, we investigated the effect of gabapentin on GABAergic transmission in CeA slices, on e

188 potential effect of systemic and intrathecal gabapentin on tactile allodynia induced by resiniferotox

189 -controlled trial was to study the effect of gabapentin on the perception of pruritus and its behavio

190 ents with downbeat nystagmus will respond to gabapentin or baclofen.

191 endent processes with Cavalpha2delta1 ligand gabapentin or genetic Cavalpha2delta1 knockdown blocks T

192 n period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo.

193 Patients were randomized to the study drug (gabapentin or placebo) at a starting dose of 300 mg oral

194 Hot flashes can be managed with venlaxafine, gabapentin, or-potentially-stress management.

195 he SF-36 and POMS also significantly favored gabapentin (P< or =.01).

196 d sleep interference showed improvement with gabapentin (P<.001).

197 tion have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no

198 Topiramate, onabotulinum toxin type A, gabapentin, petasites and tizanidine are among the agent

199 and thromboembolic stroke patients, whereas gabapentin/pregabalin were favored in subarachnoid hemor

200 rs of the glutamatergic system, riluzole and gabapentin, prolong survival.

201 Safety information was defined for gabapentin, propofol, sevoflurane, the combination of ri

202 Systemic gabapentin reduced ethanol intake in dependent, but not

203 the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only

204 We found that (i) gabapentin reduced the activations in the bilateral oper

205 Primidone, propranolol, and gabapentin reduced the amplitude (power) of the patholog

206 Overall, our results suggest that gabapentin reduces the number of beta4a-bound Ca(v)2.1 c

207 A gabapentin regimen (topical or oral) had been recommende

208 gabapentin on CeA neurons, and suggest that gabapentin represents a potential medication for treatme

209 Collectively, these findings show that gabapentin reverses behavioral measures of ethanol depen

210 d GEPR-9s, and this effect may contribute to gabapentin's effectiveness in anxiety and pain in which

211 Importantly, gabapentin's effects on drug seeking were not due to a g

212 Gabapentin seems to decrease hot flashes by approximatel

213 Using a rat neuropathic pain model in which gabapentin-sensitive tactile allodynia develops after ti

214 Gabapentin significantly reduced APN median eye speed in

215 Relative to placebo, gabapentin significantly reduced cannabis use as measure

216 Trials were for off-label uses of gabapentin sponsored by Pfizer and Parke-Davis, and docu

217 em, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, on

218 Spinal administration of the anticonvulsant gabapentin suppresses allodynia by an unknown mechanism.

219 ible acute renal dysfunction after beginning gabapentin therapy for chronic pain due to diabetic neur

220 Mood and quality of life also improve with gabapentin therapy.

221 Gabapentin (titrated from 900 to 3600 mg/d or maximum to

222 The addition of gabapentin to naltrexone improved drinking outcomes over

223 by their ability to inhibit binding of [(3)H]gabapentin to pig brain membranes and for their potency

224 The ability of gabapentin to suppress this pathway may be important for

225 used to communicate favorable messages about gabapentin to their physician colleagues.

226 Lamotrigine, gabapentin, topiramate, and oxcarbazepine are available

227 Systemic baclofen, gabapentin, tramadol, and morphine dose-dependently atte

228 A significantly greater proportion of gabapentin-treated patients compared with placebo-treate

229 Gabapentin-treated patients displayed a significantly gr

230 By intent-to-treat analysis, gabapentin-treated patients' mean daily pain score at th

231 atistically significant differences favoring gabapentin treatment were observed in measures of qualit

232 The three gabapentin trials decreased hot flashes by 35% to 38% co

233 The SSRIs or SNRIs, clonidine, and gabapentin trials provide evidence for efficacy; however

234 normalities with neurological symptoms, with gabapentin-type anticonvulsants, and is among the first

235 mg/day [N=50]), naltrexone (50 mg/day) with gabapentin (up to 1,200 mg/day [N=50]) added for the fir

236 ted a double-blind crossover trial comparing gabapentin (up to 900 mg/day) to baclofen (up to 30 mg/d

237 Gabapentin users had increased risk in subgroups of youn

238 signed to receive both an antidepressant and gabapentin versus being weaned off the antidepressant an

239 o or fewer, 0.87, 0.85-0.90), and treatment (gabapentin vs carbamazepine, 0.71, 0.59-0.86; topiramate

240 The dose of gabapentin was 1,800 mg per os, in a single administrati

241 The promotion of gabapentin was a comprehensive and multifaceted process.

242 Gabapentin was also associated with significantly greate

243 Gabapentin was associated with an increase in mean HSA,

244 or baseline values); only the higher dose of gabapentin was associated with significant decreases in

245 ed whether the combination of naltrexone and gabapentin was better than naltrexone alone and/or place

246 This effect did not endure after gabapentin was discontinued.

247 Gabapentin was generally well tolerated.

248 or not the antidepressant was continued when gabapentin was started, there was an approximately 50% m

249 ts with APN, the reduction of nystagmus with gabapentin was substantial and 8 of these elected to con

250 In the 2.3% with demyelinating disease, gabapentin was the most likely second analgesic (50.0%).

251 atistically significant differences favoring gabapentin were reported.

252 the effectiveness of the anticonvulsant drug gabapentin, which is a specific inhibitor of BCATc.

253 ocally perfused pramipexole, ropinirole, and gabapentin, which significantly counteracted optogenetic

254 Some newer antidepressants and gabapentin, within 4 weeks of therapy initiation, decrea

255 lozapine, duloxetine, clonazepam, ramelteon, gabapentin, zonisamide, and yokukansan.